TY - JOUR
T1 - Corrigendum to “van Bommel EJM, Muskiet MHA, van Baar MJB, et al. The renal hemodynamic effects of the SGLT2 inhibitor dapagliflozin are caused by post-glomerular vasodilatation rather than pre-glomerular vasoconstriction in metformin-treated patients with type 2 diabetes in the randomized, double-blind RED trial.” Kidney Int. 2020;97:202–212 (Kidney International (2020) 97(1) (202–212), (S0085253819309913), (10.1016/j.kint.2019.09.013))
AU - van Bommel, E. J. M.
AU - Muskiet, M. H. A.
AU - van Baar, M. J. B.
PY - 2020/5
Y1 - 2020/5
N2 - The authors regret an error in Supplementary Figure S1. Of patients treated with dapagliflozin, 24 were analyzed; of those treated with gliclazide, 20 were analyzed. The authors would like to apologize for any inconvenience caused.
AB - The authors regret an error in Supplementary Figure S1. Of patients treated with dapagliflozin, 24 were analyzed; of those treated with gliclazide, 20 were analyzed. The authors would like to apologize for any inconvenience caused.
UR - http://www.scopus.com/inward/record.url?scp=85083008843&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.kint.2020.03.009
DO - https://doi.org/10.1016/j.kint.2020.03.009
M3 - Comment/Letter to the editor
C2 - 32331584
SN - 0085-2538
VL - 97
SP - 1061
EP - 1061
JO - Kidney International
JF - Kidney International
IS - 5
ER -